The Last 10% Tariff Trap: A New Chapter in U.S.–China Negotiations on “Fentanyl Tariffs”

When Donald J. Trump boarded Air Force One on October 31 2025 and told reporters he was “very willing to get rid of the extra 10%” of the so-called “fentanyl tariff” levied on Chinese goods, he signalled a subtle but meaningful shift in the U.S.–China trade relationship. Just a day earlier, a framework agreement between the U.S. and Xi Jinping had reduced that particular tariff from 20% to 10%, and the White House described the move as “effective immediately.” 

At first glance this appears as a minor numerical change—but in fact, it speaks to a broader theme: the transition from blunt tariff warfare toward structured trade negotiation. In the interview, Trump praised the bilateral meeting as “incredible” and stated that the deal he and Xi reached would be “long-lasting.” Those remarks reflect an American willingness to pivot away from maximum coercion and toward calibrated resolution.

The halving of the fentanyl-related tariff therefore is more than a tax tweak—it is a signalling mechanism. By cancelling the remaining 10% on Chinese goods tied to the epidemic of synthetic opioids, the U.S. offered China a path out of being among the most heavily-tariffed countries globally—dropping its average rate from around 57% to approximately 47%. China, in return, committed to curbing the flow of fentanyl precursors and to deeper cooperation on farm trade and rare-earth exports. 

Behind the headlines lies a strategic playbook. The “fentanyl tariff” was introduced as a novel instrument of economic statecraft—linking narcotics policy with trade barriers—so lowering it suggests the U.S. is deploying tariffs as a flexible tool rather than a blunt weapon. Meanwhile, China’s role morphs from adversary to cooperating partner in a larger negotiation matrix.

For Chinese exporters, the practical effect is immediate: the reduction eases a portion of America’s tariff burden on steel, aluminum, auto-parts and other goods, although those items were not formally part of the fentanyl framework. The broader implication is that export-sensitive firms should treat this as a structural indicator rather than a one-off relief. The real question becomes whether China leverages this moment to climb further up the value chain—with better compliance, higher-end production and supply-chain resilience—or remains locked in low-margin exports.

Yet significant uncertainties persist. The tariff change comes without full transparency on enforcement mechanisms. While the release specifies the U.S. will “halve the 20% fentanyl tariff,” it offers little clarity on China’s concrete actions beyond vague commitments. Analysts warn that the agreement is a framework rather than a fully-ratified treaty, and its smooth implementation will depend on future linkages across rare-earths export policy, technology controls and agricultural access. 

From a supply-chain vantage, the deal flips a key signal: Chinese upstream suppliers of inputs to U.S. manufacturing may enjoy a degree of tariff relief, which could reduce cost headwinds for U.S. firms dependent on those inputs. At the same time, this may accelerate the rebundling of production networks, with China repositioning as a strategic hub for higher-value inputs—rather than simply low-cost volume exports.

This episode stands at a potential inflection in the broader U.S.–China trade saga. Should both parties translate framework commitments into credible milestones, the new phase could emphasise ongoing calibration, rather than episodic escalation. If not, the tariff reduction may merely mark a temporary thaw before the next freeze. In either case, corporate planners must treat the “last 10%” cancellation as part of an evolving architecture—and design their strategies accordingly.